Drugs / PV701
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00081211 | Apr → Jul 2004 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma, nasopharyngeal squamous cell carcinoma +2 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00055705 | Jan 2003 → ? | cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PV701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00055705 ↗ |
| Modality | Vaccine | “Vaccines made from a specially-modified virus such as PV701 may make the body build an immune response to kill tumor cells while leaving normal cells undamaged” NCT00081211 ↗ |
| Route | Intravenous | “Patients receive PV701 IV over 30 minutes” NCT00055705 ↗ |